Brought to you by 
eFFECTOR, Merck, and Pfizer commence combo trial for microsatellite stable CRC
18 Oct 2021
Executive Summary
Pfizer Inc., Merck KGAA, and eFFECTOR Therapeutics Inc. entered into a trial collaboration agreement to study a combination of Merck and Pfizer’s avelumab with eFFECTOR’s eFT508 as a potential treatment for microsatellite stable colorectal cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
eFFECTOR, Merck, and Pfizer commence combo trial for microsatellite stable CRC
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice